Scholar Rock Holding Past Earnings Performance
Past criteria checks 0/6
Scholar Rock Holding's earnings have been declining at an average annual rate of -26.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 4.5% per year.
Key information
-26.2%
Earnings growth rate
-4.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 4.5% |
| Return on equity | -73.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?
Apr 15
Scholar Rock: Solid Data And Good Prospects
Jan 12Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up
Apr 19Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
Oct 20Jay Backstrom is the new CEO at Scholar Rock
Sep 20Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology
Jul 12Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts
May 21Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher
Mar 08Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be
May 15Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?
May 07If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today
Mar 01We Think Scholar Rock Holding (NASDAQ:SRRK) Can Afford To Drive Business Growth
Jan 05
Scholar Rock EPS misses by $0.23, misses on revenue
Nov 09Scholar Rock Is At Phase 2, $1 Billion Is Too Expensive
Nov 04Scholar Rock prices ~$200M equity offering.
Oct 29Revenue & Expenses BreakdownBeta
How Scholar Rock Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -166 | 49 | 0 |
| 30 Sep 23 | 0 | -159 | 47 | 0 |
| 30 Jun 23 | 0 | -160 | 44 | 0 |
| 31 Mar 23 | 0 | -166 | 43 | 0 |
| 31 Dec 22 | 33 | -135 | 43 | 0 |
| 30 Sep 22 | 37 | -131 | 43 | 0 |
| 30 Jun 22 | 43 | -125 | 43 | 0 |
| 31 Mar 22 | 47 | -112 | 42 | 0 |
| 31 Dec 21 | 19 | -132 | 40 | 0 |
| 30 Sep 21 | 18 | -122 | 38 | 0 |
| 30 Jun 21 | 16 | -109 | 35 | 0 |
| 31 Mar 21 | 15 | -97 | 32 | 0 |
| 31 Dec 20 | 15 | -86 | 28 | 0 |
| 30 Sep 20 | 20 | -71 | 26 | 0 |
| 30 Jun 20 | 21 | -64 | 24 | 0 |
| 31 Mar 20 | 22 | -57 | 23 | 0 |
| 31 Dec 19 | 20 | -51 | 21 | 0 |
| 30 Sep 19 | 13 | -54 | 20 | 0 |
| 30 Jun 19 | 8 | -49 | 17 | 0 |
| 31 Mar 19 | 3 | -51 | 16 | 0 |
| 31 Dec 18 | 0 | -49 | 14 | 0 |
| 30 Sep 18 | 0 | -43 | 11 | 0 |
| 30 Jun 18 | 0 | -38 | 9 | 0 |
| 31 Mar 18 | 0 | -29 | 6 | 0 |
| 31 Dec 17 | 0 | -25 | 5 | 0 |
| 31 Dec 16 | 0 | -16 | 4 | 0 |
Quality Earnings: SRRK is currently unprofitable.
Growing Profit Margin: SRRK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SRRK is unprofitable, and losses have increased over the past 5 years at a rate of 26.2% per year.
Accelerating Growth: Unable to compare SRRK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRRK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: SRRK has a negative Return on Equity (-73.61%), as it is currently unprofitable.